NOK 2.49
(3.11%)
Year | Operating Income | Operating Income Growth |
---|---|---|
2023 | -7.16 Million NOK | 0.0% |
2022 | - NOK | 100.0% |
2021 | -442.43 Million NOK | -1.91% |
2020 | -434.16 Million NOK | 0.0% |
Year | Operating Income | Operating Income Growth |
---|---|---|
2024 Q1 | -6550.00 NOK | 0.0% |
2024 Q2 | -6550.00 NOK | 0.0% |
2023 Q1 | -13.25 Thousand NOK | 0.0% |
2023 FY | -7.16 Million NOK | 0.0% |
2023 Q2 | -13.25 Thousand NOK | 0.0% |
2022 FY | - NOK | 100.0% |
2021 FY | -442.43 Million NOK | -1.91% |
2020 FY | -434.16 Million NOK | 0.0% |
Name | Operating Income | Operating Income Difference |
---|---|---|
Arctic Bioscience AS | -48.58 Million NOK | 85.263% |
Aqua Bio Technology ASA | -17.85 Million NOK | 59.904% |
ArcticZymes Technologies ASA | 15.74 Million NOK | 145.472% |
BerGenBio ASA | -191.81 Million NOK | 96.267% |
Hofseth BioCare ASA | -102.52 Million NOK | 93.017% |
PCI Biotech Holding ASA | -22.24 Million NOK | 67.807% |
Ultimovacs ASA | -215.73 Million NOK | 96.681% |